Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Andrew Marks
Columbia University Health Sciences, Department: Physiology
Should you be removed from our database? Contact us at [email protected]. Read more below.
ARMGO Pharma
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Marks owns equity in ARMGO Pharma Inc. and is a member of the company’s Board of Directors and chairman of the Scientific Advisory Board. (In prior years, Columbia reported that Dr. Marks also received significant annual payments from the company, but he no longer receives those payments.) In addition, ARMGO has licensed intellectual property from Columbia arising from Dr. Marks’ Columbia lab, and is engaged in drug development involving this technology. The company’s efforts may benefit from the outcome of the research under this grant. In light of these factors, Columbia has determined that the outcome of this research could affect the company and Dr. Marks’ financial interests in ARMGO, and that the design, conduct, and/or reporting of this research could be affected by Dr. Marks’ interests in ARMGO.
Structure-function analysis for elucidating pathogenicity of cardiac ryanodine receptor genetic variants
Project Narrative Patients with CPVT have mutations in the cardiac ryanodine receptor/calcium release channels that cause the channel to become ?leaky,? which, during exercise, results in pathologic cellular calcium overload, delayed-after-depolarizations, and lethal arrhythmias. Given the large size of RyR2 it is unclear how mutations in different parts of the channel have similar effects on channel function, and the rarity of this disease makes it difficult to assign pathogenicity to newly identified variants that are associated with lethal arrhythmias. By solving the cryo-EM structure of two RyR2-CPVT mutants in multiple states, testing these mutations using a novel high-bandwidth, high-throughput lipid bilayer system, and developing a comprehensive database of RyR2 variants associated with CPVT, we will advance the understanding of how CPVT mutations cause clinical disease and provide a framework for assigning pathogenicity to variants of unknown significance.
Filed on July 08, 2019.
Tell us what you know about Andrew Marks's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Andrew Marks filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Andrew Marks | Indiana Univ Purdue Univ at Indianapolis | Conflict of Interest | ARMGO Pharma Inc | $250,000 - $299,999 |
| Andrew Marks | Columbia University Health Sciences | Conflict of Interest | ARMGO | $250,000 - $299,999 |
| Andrew Marks | Columbia University Health Sciences | Conflict of Interest | ARMGO | $250,000 - $299,999 |
| Andrew Marks | Columbia University Health Sciences | Conflict of Interest | ARMGO Pharma Inc. | $250,000 - $299,999 |
| Andrew Marks | Columbia University Health Sciences | Conflict of Interest | ARMGO Pharma Inc. | $0 - $4,999 |
| Andrew Marks | Indiana Univ Purdue Univ at Indianapolis | Conflict of Interest | ARMGO Pharma Inc | Value cannot be readily determined |
| Andrew Marks | Columbia University Health Sciences | Conflict of Interest | ARMGO Pharma | Value cannot be readily determined |
| Andrew Marks | Columbia University Health Sciences | Conflict of Interest | ARMGO Pharma | Value cannot be readily determined |
| Andrew Marks | Columbia University Health Sciences | Conflict of Interest | ARMGO | Value cannot be readily determined |
| Andrew Marks | Columbia University Health Sciences | Conflict of Interest | ARMGO Pharma | Value cannot be readily determined |
| Andrew Marks | Columbia University Health Sciences | Conflict of Interest | ARMGO | Value cannot be readily determined |
| Andrew Marks | Columbia University Health Sciences | Conflict of Interest | ARMGO Pharma Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.